129 related articles for article (PubMed ID: 30309223)
1. Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology.
Ha H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
Cancer Res Treat; 2019 Apr; 51(2):832-840. PubMed ID: 30309223
[TBL] [Abstract][Full Text] [Related]
2. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
Ha H; Nam AR; Bang JH; Park JE; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Oncotarget; 2016 Nov; 7(47):76604-76612. PubMed ID: 27780932
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients.
Park W; Bang JH; Nam AR; Jin MH; Seo H; Kim JM; Oh KS; Kim TY; Oh DY
Cancer Res Treat; 2021 Jan; 53(1):199-206. PubMed ID: 33070562
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Jin MH; Oh KS; Kim JM; Kim TY; Oh DY
Liver Int; 2021 Feb; 41(2):388-395. PubMed ID: 32780918
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Park H; Bang JH; Nam AR; Eun Park J; Hua Jin M; Bang YJ; Oh DY
Sci Rep; 2019 Jul; 9(1):11131. PubMed ID: 31366979
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Park H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
Cancer Med; 2020 Jan; 9(1):43-51. PubMed ID: 31701645
[TBL] [Abstract][Full Text] [Related]
9. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
[TBL] [Abstract][Full Text] [Related]
12. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
15. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
16. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
[TBL] [Abstract][Full Text] [Related]
17. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
18. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]